Abstracts tagged "interferon"

Abstract Number: 1862 • ACR Convergence 2022
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Thomas Vazquez¹, Meena Sharma¹, Rui Feng², DeAnna Diaz³, Nilesh Kodali¹, Josh Dan³, Madison Grinnell³, Emily Keyes³, Grant Sprow³, Barbara White⁴ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Pleasanton, CA
Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…
Abstract Number: 0359 • ACR Convergence 2022
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
Ronald Van Vollenhoven¹, Eric F. Morand², Richard A. Furie³, Ian N. Bruce⁴, Gabriel Abreu⁵, Raj Tummala⁶, Hussein Al-Mossawi⁷ and Catharina Lindholm⁸, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, Amsterdam, Netherlands, ²Monash University, Melbourne, Australia, ³Northwell Health, Great Neck, NY, ⁴The University of Manchester, Manchester, United Kingdom, ⁵AstraZeneca, Mölndal, Sweden, ⁶AstraZeneca, Gaithersburg, MD, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸AstraZeneca, Gothenburg, Sweden
Background/Purpose: In patients with SLE, achieving remission is a treat-to-target goal. Remission is associated with lower rates of hospitalization and damage accrual and better quality…
Abstract Number: 0669 • ACR Convergence 2022
Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
Thomas Li¹, Ethan Seltzer¹, Victoria Zyulina¹, Keila Veiga², Noa Schwartz³, Yurii Chinenov¹, David Oliver¹, Jose Lora⁴, Ali Jabbari⁵, Yong Liu¹, Hafsa Munir¹, William Shipman¹, Marvin Sandoval¹, Isabel Sollohub¹, william ambler¹, Bikash Mishra⁴, sarah taber¹, karen onel¹, Mehdi Rashighi⁶, james krueger⁷, Niroshana Anandasabapathy⁴, Carl Blobel¹ and theresa Lu¹, ¹Hospital for Special Surgery, New York, NY, ²Maria Fareri Children's Hospital, New York, NY, ³Albert Einstein College of Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵University of Iowa, Iowa City, IA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Rockefeller University, New York, NY
Background/Purpose: Photosensitivity is a hallmark symptom of lupus erythematosus (LE), in which patients develop inflammatory skin lesions in response to ultraviolet radiation (UVR). In examining…
Abstract Number: 1879 • ACR Convergence 2022
Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies
jiram torres-Ruiz¹, Abdiel Absalón-Aguilar², Juan Alberto Reyes-Islas², Alfredo Pérez-Fragoso², Nancy R Mejía-Domínguez³, guillermo Juárez-Vega⁴, Alejandro Alfaro-Goldaracena⁵, Beatriz Alcalá-Carmona², Guillermo Juárez-Vega³, Fabiola Cassiano-Quezada² and Diana Gómez-Martín¹, ¹INCMNSZ, Ciudad de México, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación. UNAM, Ciudad de México, Mexico, ⁵Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Muscle atrophy is mediated by the ubiquitination of myofilaments by two ubiquitin ligases called Tripartite Motif Containing (TRIM) 63 and Atrogin-1, which are induced…
Abstract Number: 0360 • ACR Convergence 2022
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Mark Lazarus¹, Paul Newcombe¹, Richard A. Furie², Philip Brohawn³, Wendy White³, Dominic Sinibaldi³, Nicola Ferrari¹, Raj Tummala³, Hussein Al-Mossawi¹, Edward Vital⁴, Eric F. Morand⁵, Daniel Muthas⁶ and Madhu Ramaswamy³, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³AstraZeneca, Gaithersburg, MD, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Monash University, Melbourne, Australia, ⁶AstraZeneca, Gothenburg, Sweden
Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…
Abstract Number: 0740 • ACR Convergence 2022
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
Carl Allen¹, Shanmuganathan Chandrakasan², Michael Jordan³, Jennifer Leiding⁴, Abiola Oladapo⁵, Priti Pednekar⁶, Kelly Walkovich⁷ and John Yee⁸, ¹Baylor College of Medicine, Houston, TX, ²Emory University School of Medicine, Atlanta, GA, ³University of Cincinnati, Cincinnati, OH, ⁴Johns Hopkins University, Baltimore, MD, ⁵Swedish Orphan Biovitrum AB, Boston, MA, ⁶PRECISIONheor, Los Angeles, CA, ⁷University of Michigan Health, Ann Arbor, MI, ⁸Sobi - North America, Waltham, MA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome caused by overproduction of proinflammatory cytokines, e.g., interferon gamma (IFNγ). Secondary HLH (sHLH), a subtype…
Abstract Number: 1931 • ACR Convergence 2022
NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis
Esraa Eloseily¹, Alexander Valencia², Astha Malik², Rebekah Karns², Cyd Castro Rojas², Mosab Alquraish², Rebecca Marsh³, Alexei Grom⁴ and Alexander Miethke², ¹Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Bone Marrow Transplantation & Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Mutations in the gene NOD2 encoding the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) which controls innate responses to LPS have been linked to Blau…
Abstract Number: L20 • ACR Convergence 2021
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
Fabrizio De Benedetti¹, Alexei Grom², Paul Brogan³, Claudia Bracaglia¹, Manuela Pardeo¹, Giulia Marucci¹, Despina Eleftheriou³, Charalampia Papadopoulou³, Pierre Quartier⁴, Jordi Antón⁵, Rikke Frederiksen⁶, Veronica Asnaghi⁶ and Cristina De Min⁶, ¹Bambino Gesù Children's Hospital IRCCS, Rome, Italy, ²Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, ⁶Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
Abstract Number: 1273 • ACR Convergence 2021
A 12-week Aerobic Exercise Training Program in Women with Systemic Lupus Erythematosus (SLE) Improves Fatigue, Mitochondrial Dysfunction and Associated Interferon Gene Signature
Sarfaraz Hasni¹, Marquis Chapman², Rebekah Feng¹, Anam Ahmad¹, Sarthak Gupta³, Mohammad Naqi¹, Adam Munday¹, Shajia Lu¹, Massimo Gadina², Zerai Manna¹, Xiaobai Li⁴, Yinghui Shi¹, Kalyani Mishra-Thakur¹, Michael Davis⁵, Jun Chu³, Elaine Poncio⁶, Yenealem Temesgen-Oyelakin⁷, Jonathan Martinez¹, Zoe Morris¹, Isabel Ochoa⁶, Shuichiro Nakabo⁸, Bart Drinkard¹, Gayle McCrossin¹, Marybeth Stockman¹, Mariana Kaplan¹, Leorey Saligan¹, Randall Keyser⁹, Leighton Chan¹ and Lisa Chin¹, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Clinical Center, National Institutes of Health, Bethesda, MD, ⁵NIAMS, Bethesda, MD, ⁶NIH/NIAMS, Bethesda, MD, ⁷National Institutes of Health (NIH), Bethesda, MD, ⁸NIAMS/NIH, Bethesda, MD, ⁹George Mason University, Bethesda
Background/Purpose: Fatigue in SLE patients is ubiquitous and is reported as one of the most debilitating symptoms. Yet mechanisms underlying the pathophysiology of SLE-related fatigue…
Abstract Number: 1741 • ACR Convergence 2021
Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials
Kenneth Kalunian¹, Maria Dall'Era², Richard Furie³, Eric Morand⁴, Konstantina Psachoulia⁵, Emmanuelle Maho⁶, Catharina Lindholm⁷ and Raj Tummala⁵, ¹University of California, La Jolla, CA, ²University of California San Francisco, San Francisco, CA, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In 2 phase 3 trials, TULIP-1 and TULIP-2, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 Here, we…
Abstract Number: 1365 • ACR Convergence 2021
Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Amel Eman Abdulle², Anniek Van Roon², Alja J. Stel², Harry Van Goor², Andries Smit², Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Raynaud’s Phenomenon (RP) leading to repetitive ischaemia and reperfusion (IR) stress, is the first recognisable sign of systemic sclerosis (SSc). Although RP has been…
Abstract Number: 1742 • ACR Convergence 2021
Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials
Ian N. Bruce¹, Ronald Van Vollenhoven², Yoshiya Tanaka³, Eric Morand⁴, Richard Furie⁵, Konstantina Psachoulia⁶, Emmanuelle Maho⁷, Catharina Lindholm⁸, Christi Kleoudis⁹ and Raj Tummala⁶, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Monash University, Melbourne, Australia, ⁵Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁸BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, AstraZeneca, Durham, NC
Background/Purpose: In the TULIP-2 and TULIP-1 trials of patients with SLE, the type I IFN receptor mAb anifrolumab resulted in higher BILAG–based Composite Lupus Assessment…
Abstract Number: 1432 • ACR Convergence 2021
Modulation of Auto-Inflammation with a Novel Selective Cyclic GMP-AMP Synthase (cGAS) Inhibitor in a Trex1-/- Model
Kelly Pike¹, Alexandre Caron¹, Emilie Bérubé¹, Ramsay Beveridge¹, Marc-Oliver Boily¹, Jason Burch¹, Valerie Dumais¹, Nadine Fradet¹, Samuel Gaudreault¹, Daniel McKay¹, Marianne Raymond¹, Eleftheria Seliniotakis¹, Daniel Sietsema³, Alexander Skeldon¹, Miguel St.-Onge¹, Li Wang² and Michael Crackower², ¹Ventus Therapeutics, Montréal, QC, Canada, ²Ventus Therapeutics, Waltham, MA

Background/Purpose: The detection of viral nucleic acids (NA) elicits a transient type I interferon (IFN) response central to antiviral immunity. Chronic type I IFN responses…
Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Ranjitha Karanth¹, Giuseppina Abignano², Vishal Kakkar², Rebecca Ross², Christopher Denton³ and Francesco Del Galdo², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
Abstract Number: 1439 • ACR Convergence 2021
Inhibitors of Endogenous Reverse Transcriptases Suppress in Vitro Type I Interferon Responses and in Vivo Antigen-specific T Cell Responses
Nafeeza Hafeez, Jimmy Zhong, Jared Steranka, Margit Hagel, Greg Bisacchi, Donna Romero, Rosana Kapeller, Dennis Zaller and Wenyan Miao, Rome Therapeutics, Cambridge, MA
Background/Purpose: Transposable elements (TEs) are mobile DNA elements that can replicate and move from one position to another within the host genome. Through co-evolution, TEs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].